Page 1

ORGANON " Karissa Peer ( 614 ) 314-8094 Media Contacts : Kate Vossen ( 732 ) 675-8448 Investor Contacts : Jennifer Halchak ( 201 ) 275-2711 Edward Barger ( 267 ) 614-4669 Exhibit 99.1 Organon reports results for the second quarter ended June 30 , 2021 and announces inaugural dividend Second quarter 2021 revenue of $ 1,595 million Net income from continuing operations of $ 431 million , or $ 1.70 per diluted share ; Adjusted net income from continuing operations of $ 437 million , or $ 1.72 per diluted share Adjusted EBITDA of $ 627 million Board of Directors declares quarterly dividend of $ 0.28 per share Financial guidance affirmed for 2021 Jersey City , N.J. , August 12 , 2021 - Organon ( NYSE : OGN ) ( the " company " ) , today announced its results for the second quarter and year to date ended June 30 , 2021 and affirmed its full year 2021 financial guidance . Organon also announced that its Board of Directors declared a quarterly dividend of $ 0.28 for each issued and outstanding share of the company's common stock . The dividend is payable on September 13 , 2021 to stockholders of record at the close of business on August 23 , 2021 . " Since well before Organon's June 2nd spin - off from Merck , thousands of employees have been hard at work standing up Organon , committed to a shared vision to advance the health of women . Already , we have demonstrated our commitment to identifying potential opportunities to help address some of the most important unmet needs in women's health , with an acquisition focused on treating post - partum hemorrhage as well as a licensing agreement to develop an investigational agent being evaluated to delay pre - term labor , " said Kevin Ali , CEO of Organon . " At the same time , we are focused on driving our business , with all three of our franchises delivering on their objectives .